Pharmaceuticals company Marksans Pharma announced Q4FY23 & FY23 results: Q4FY23: Operating revenue was Rs 486.0 crore, up by +16.3% YoY driven by market share gains in the existing products and markets US business grew by +12.8% YoY UK and Europe grew by +33.1% YoY Gross profit was Rs 242.1 crore, up by +17.3% YoY with a Gross margin of 49.8% EBITDA was Rs 109.5 crore, grew by 72.1% with an EBITDA margin of 22.5% EPS grew by 185.5% YoY to Rs 2.0 FY23: Operating revenue at Rs 1,852.1 crore, increased by 24.2% YoY Gross profit at Rs 930.8 crore, grew by +20.3% YoY with a Gross margin at 50.3% EBITDA at Rs 339.3 crore, increased 31.1% YoY with EBITDA margin at 18.3% Cash balance stood at a healthy Rs 715.0 crore as of 31st March 2023 Free Cash Flow was Rs 183.8 crore Mark Saldanha, Managing Director of the company said, "Our consistent growth trend continues in the quarter, driven by gains in existing store brands, products, and markets, as well as normalization of freight expenses. We have completed the acquisition of Teva Pharma manufacturing unit in Goa which will enable us to accelerate the growth of our business and strengthen our position as a leading low-cost manufacturer. We have exceeded our FY23 guidance of Rs 1,800 crore. This milestone is our testament to our commitment to delivering value creation for our stakeholders. We aim to continue our success in the coming year, with a focus on extending our footprint in the multi-billion-dollar OTC opportunities, focusing on margin improvement, and strengthening our balance sheet”. Result PDF